

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Application No.: 09/070,629

Filed: April 30, 1998

For: RECOMBINANT INFLUENZA  
VIRUSES EXPRESSING TUMOR-  
ASSOCIATED ANTIGENS AS  
ANTITUMOR AGENTS



Group Art Unit: 1641

Examiner: Laurie Scheiner

Attorney Docket No.: 6923-071

RECEIVED

DEC 04 2000

TECH CENTER 1600/2900

## FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.

The claim amendment fee has been estimated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		SMALL ENTITY		OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE
TOTAL	63	MINUS	0	=	63	× 9	\$	× 18	\$ 0.00
INDEP.	1	MINUS	3	=	0	× 39	\$	× 80	\$ 0.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					130	\$		+ 260	\$ 0.00
TOTAL						\$	OR	TOTAL	\$ 0.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.  
A copy of this sheet is enclosed.

Date November 24, 2000Respectfully submitted, by *Jacqueline Ben**Laura A. Coruzzi*

Laura A. Coruzzi

Ref No. 43,492

30,742

(Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosure

#14/B  
12-9-00  
RP

EXPRESS MAIL NO.: EL 564 218 503 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Palese et al.

Application No.: 09/070,629

Filed: April 30, 1998

For: RECOMBINANT INFLUENZA  
VIRUSES EXPRESSING TUMOR-  
ASSOCIATED ANTIGENS AS  
ANTITUMOR AGENTS



Group Art Unit: 1641

Examiner: Laurie Scheiner

Attorney Docket No.: 6923-071

**AMENDMENT UNDER 37 C.F.R. § 1.111**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action dated May 24, 2000, and in accordance with Rule 111 of the Rules of Practice, please enter the following amendments and consider the following remarks intended to put this application into form for allowance. Applicants submit herewith: (1) a Fee Transmittal Sheet for the additional claims, accompanied by the appropriate fee; (2) a Petition To Extend Time, accompanied by the appropriate fee; (3) an Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97; (4) a revised form PTO 1449; and (5) a copy of the pending claims as amended herein, attached hereto as Exhibit A.

**IN THE CLAIMS:**

Please amend the claims as follows:

Cancel Claims 6, 9, and 12-19 without prejudice.

Amend Claims 2, 4 and 5 as follows:

2. (amended) The recombinant influenza virus of Claim 1, 20, 21, 22, 23, 24  
or 25 in which the region is contained within a structural gene of influenza virus.